# Wenda Pharmaceutical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/wenda-pharmaceutical

- Industry: Biotechnology
- Headquarters: Ningbo, China
- Website: http://www.nbyyz.com/
- Total disclosed funding: $15M
- Latest round: Series A (Jul 27, 2021)
- Investors on record: 3

## About

Established in 2013 and based in Ningbo, China, Wenda Pharmaceutical is a company that engages in the research and development of small molecule targeted drugs. The founder of the company, Wang Nenghui, has 25 years of R&D experience in well-known overseas multinational pharmaceutical companies. The company has a wholly-owned subsidiary, Hunan Hengya Pharmaceutical Technology Co., Ltd., which is the first approved class 1.1 original drug research and development enterprise in Hunan Province.

The company mainly develops BET inhibitors, TYK2 inhibitors, KRAS targeted drugs and other drugs for the treatment of cancer, psoriasis, rheumatoid arthritis, IBD and other diseases.

## Funding rounds

- Series A, Jul 27, 2021, $15M — Lapam Capital, KXX Culture Investment, Sealyoung Capital

## Investors

- Lapam Capital (https://capitalatlas.ai/funds/lapam-capital) — Series A
- KXX Culture Investment (https://capitalatlas.ai/funds/kxx-culture-investment) — Series A
- Sealyoung Capital — Series A